Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis

Marie-Christine Reinert, MD, Pascal Benkert, PhD, Jens Wuerfel, MD, Zuzanna Michalak, PhD, Esther Ruberte, PhD, Christian Barro, MD, Peter Huppke, MD, Wiebke Stark, MD, Harald Kropshofer, PhD, Davorka Tomic, PhD, David Leppert, MD, Jens Kuhle, MD, PhD, Wolfgang Brück, MD, and Jutta Gartner, MD

Neurol Neuroimmunol Neuroinflamm 2020;7:e749. doi:10.1212/NXI.0000000000000749

Correspondence
Dr. Reinert
marie-christine.reinert@med.uni-goettingen.de

Abstract

Objective
To investigate serum neurofilament light chain (sNfL) as a potential biomarker for disease activity and treatment response in pediatric patients with multiple sclerosis (MS).

Methods
In this retrospective cohort study, sNfL levels were measured in a pediatric MS cohort (n = 55, follow-up 12–105 months) and in a non-neurologic pediatric control cohort (n = 301) using a high-sensitivity single-molecule array assay. Association of sNfL levels and treatment and clinical and MRI parameters were calculated.

Results
Untreated patients had higher sNfL levels than controls (median 19.0 vs 4.6 pg/mL; CI [4.732, 6.911], p < 0.001). sNfL levels were significantly associated with MRI activity (+9.1% per contrast-enhancing lesion, CI [1.045, 1.138], p < 0.001; +0.6% per T2-weighted lesion, CI [1.001, 1.010], p = 0.015). Higher values were associated with a relapse <90 days ago (+51.1%; CI [1.184, 1.929], p < 0.001) and a higher Expanded Disability Status Scale score (CI [1.001, 1.240], p = 0.049). In patients treated with interferon beta-1a/b (n = 27), sNfL levels declined from 14.7 to 7.9 pg/mL after 6 ± 2 months (CI [0.339, 0.603], p < 0.001). Patients with insufficient control of clinical or MRI disease activity under treatment with interferon beta-1a/b or glatiramer acetate who switched to fingolimod (n = 18) showed a reduction of sNfL levels from 16.5 to 10.0 pg/mL 6 ± 2 months after switch (CI [0.481, 0.701], p < 0.001).

Conclusions
sNfL is a useful biomarker for monitoring disease activity and treatment response in pediatric MS. It is most likely helpful to predict disease severity and to guide treatment decisions in patients with pediatric MS. This study provides Class III evidence that sNfL levels are associated with disease activity in pediatric MS.

From the Department of Pediatrics and Adolescent Medicine (M.-C.R., P.H., W.S., J.G.), Division of Pediatric Neurology, University Medical Centre Göttingen, Georg August University Göttingen, Germany; Clinical Trial Unit (P.B.), Department of Clinical Research, University Hospital Basel, University of Basel; Medical Image Analysis Centre Basel (MIAC AG) (J.W., E.R.); Department of Biomedical Engineering (J.W.), University Basel; Neurologic Clinic and Polyclinic (Z.M., C.B., D.L., J.K.), Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel; Novartis Pharma AG (H.K., D.T.), Basel, Switzerland; and Institute of Neuropathology (W.B.), University Medical Centre Göttingen, Georg August University Göttingen, Germany.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by Georg August University Göttingen.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Disability Status Scale; MRI. We also hypothesized lower sNfL levels in pediatric than adult patients with MS compared with controls and treatment response in pediatric MS. We hypothesized elevated sNfL levels in children with MS compared with controls and correlation with clinical parameters such as EDSS score and MRI. We also hypothesized lower sNfL levels in pediatric than in adult controls due to age dependency.

Classification of evidence is Class III evidence.

**Patients and samples**

We analyzed a cohort of pediatric patients with MS (n = 55) and non-neurologic pediatric controls (n = 301) recruited in the Department of Pediatrics and Adolescent Medicine, University Medical Centre Göttingen, Germany.

Patients with MS fulfilled the following inclusion criteria: (1) confirmed diagnosis of MS according to the McDonald criteria 2017, (2) disease onset <18 years, and (3) retrospective clinical data and serum samples available for ≥12 months of follow-up. We defined 2 treatment cohorts:

1. **Interferon (IFN)** group (n = 27): patients treated with IFN beta-1a or -1b during complete follow-up.
2. **Switching DMT** group (n = 28): patients switched from IFN, glatiramer acetate (GA), natalizumab, or dimethyl fumarate to fingolimod during follow-up. As a subgroup, we defined the fingolimod group (n = 18, treatment switch from IFN/GA to fingolimod).

We collected serum samples at baseline (first contact in our clinic) and follow-up visits (usually every 6 months and additional visits due to relapses) between May 2003 and March 2018 and stored at −20°C. Study size was determined by the number of patients fulfilling the criteria of the switch group and then completed by a comparable number of IFN patients. Loss of follow-up was due to reaching adulthood or switching to another treatment center and was accepted if at least 3 samples were available for this study.

The patients of the control cohort attended the hospital because of non-neurologic diseases between November 2017 and May 2018. The blood sample was taken unrelated to the study. Patients with severe/life-threatening diseases or on medication with chemotherapeutics were excluded. Diagnoses of the controls are shown in table e-1 (links.lww.com/NXI/A251).

**Standard protocol approvals, registrations, and patient consents**

Patients and parents or guardians of children younger than 18 years provided written informed consent. The study was approved by the local ethics committee.

**Measurements of sNfL with Simoa technology**

We measured sNfL levels using the high-sensitivity single-molecule array (Simoa) NF-Light Advantage Kit (Quanterix, Lexington, MA) according to the manufacturer’s instructions. We analyzes all samples in duplicate within one assay. Interassay

**Glossary**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEL</td>
<td>contrast-enhancing lesion;</td>
</tr>
<tr>
<td>CV</td>
<td>coefficient of variation;</td>
</tr>
<tr>
<td>DMT</td>
<td>disease-modifying therapy;</td>
</tr>
<tr>
<td>EDSS</td>
<td>Expanded Disability Status Scale;</td>
</tr>
<tr>
<td>GA</td>
<td>glatiramer acetate;</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon;</td>
</tr>
<tr>
<td>sNfL</td>
<td>serum neurofilament light chain.</td>
</tr>
</tbody>
</table>

**Methods**

**Research questions**

With this study, we want to answer the following questions:

1. Do pediatric patients with MS have higher sNfL levels than non-neurologic pediatric controls?
2. Do sNfL levels in pediatric patients with MS correlate with clinical disease activity?
3. Do sNfL levels in pediatric patients with MS correlate with MRI disease activity?
4. Can sNfL levels in pediatric patients with MS be used to monitor disease activity and treatment effects?
coefficients of variation (CVs) for 3 native serum samples were below 10%. The mean intra-assay CV of duplicate determinations for concentration was 5.0%. We did repeat measurements for few samples with intra-assay CV above 20%. Analyses were performed blinded to clinical or MRI data.

Clinical data
The EDSS score was rated during the regular clinical follow-up visits by a pediatric neurologist, but not during a relapse. We defined relapses as neurologic symptoms that could not be explained otherwise for lasting at least 24 hours and with the last relapse at least 30 days ago.

Cerebral MRI
In the MS cohort, we performed cerebral MRI at baseline and at follow-up visits. We quantitatively analyzed MRIs in a specialized imaging clinical research organization (Medical Image Analysis Centre, Basel, Switzerland) in a blinded manner. Lesions were marked and segmented in a standardized fashion using Amira (Mercury Computer Systems Inc., Chelmsford) by expert raters and subsequently confirmed by board certified neuroradiologists. We quantified contrast-enhancing lesion (CEL) in all available cerebral MRIs and T2-weighted (T2w) lesions as a cumulative parameter only once a year for each patient.

Statistical analysis
We described continuous and ordinary variables by median and interquartile range and categorical variables as counts and percentages. The EDSS score was not reported for some visits due to relapses and incomplete data and therefore imputed for S1 of 366 visits by using the EDSS value of the previous visit when available (otherwise of the subsequent visit).

We did the analyses involving only baseline samples using ordinary linear regression models. Thereby, the dependent variable NfL was log transformed. In the longitudinal analyses, we modeled the drop in NfL levels during the follow-up in the IFN and the switching DMT group using linear generalized estimating equation models with log(NfL) as the dependent variable. To handle repeated measures within patients, we clustered data points to account for within-subject correlation, thereby assuming an exchangeable correlation structure. With the combined data set using all patients, we investigated 2 separate models: (1) a clinical model with EDSS score, age, sex, recent relapse, and treatment status and (2) an MRI model with age, number of T2w lesions, and number of CELs (table e-2 links.lww.com/NXI/A252). All estimates were back transformed to the original scale and therefore represent multiplicative effects on the geometric mean of sNfL.

Data availability
The anonymized data can be made available on a research basis. Interested scientists can submit a request to the corresponding author. Requests for access will be reviewed, and a data access agreement will be required.

Results
Baseline characteristics
Baseline demographics and patient characteristics are shown in the table. In the switching DMT group, most patients (19 of 28, 67.9%) switched to fingolimod due to ongoing clinical (5 patients) or MRI disease activity (5 patients) or both (9 patients) under previous treatment with IFN, GA, or dimethyl fumarate.

Eight patients (28.6%) switched from natalizumab to fingolimod: 7 due to increasing risk of progressive multifocal leukoencephalopathy (antibodies against JC virus and natalizumab treatment duration ≥ 2 years) and 1 due to an allergic reaction to natalizumab. For sNfL analysis under treatment, we focused on patients switching from injectables (IFN/GA) to fingolimod (fingolimod group, n = 18).

sNfL in a pediatric control cohort
In the control group (n = 301, median age 10.1 years, range 3 months–17.9 years, 50.5% female), median sNfL was 5.1 pg/mL (3.7, 6.7). Age had a significant effect on sNfL levels (CI [0.963, 0.985], p < 0.001), with higher sNfL levels in younger children (figure 1). In controls covering the age range of patients with MS (n = 212; median age 12.5 years, range 6.5–17.9 years, 52.8% female), median sNfL was 4.6 pg/mL (3.5, 6.0). In these children, there was no significant effect of age on sNfL levels (CI [0.998, 1.026], p = 0.092). Percentiles of controls covering the age range of patients with MS are shown in figure 1. We only used these 212 patients and the percentiles calculated from their data for comparison with the patients with MS.

sNfL levels in patients with MS at baseline
In the MS cohort, 43 of 55 patients (78.2%) were untreated at baseline. Untreated patients had significantly higher sNfL values at baseline than controls (figure 2). Twenty-six of them (60.5%) had a relapse within the last 90 days associated with higher sNfL levels (30.4 pg/mL [13.3, 68.6] vs 15.9 pg/mL [12.1, 24.7]; CI [1.089, 3.711], p = 0.027).

Using a logistic regression model to predict future treatment switch in patients untreated and recently diagnosed (n = 39) with NfL as a predictor, we found an OR of 2.596 of need for higher potent drugs (fingolimod and natalizumab) during follow-up in patients with sNfL above 99th percentile of controls at baseline (CI [0.695, 5.614], p = 0.024).

Association of sNfL and cerebral MRI lesions (MRI model)
In the longitudinal analysis, sNfL levels were strongly associated with the number of T2w lesions and with the number of CELs (figure 3B; table e-2 links.lww.com/NXI/A252).

Association of sNfL levels and clinical aspects (clinical model)
The clinical model (table e-2 links.lww.com/NXI/A252, figure e-1 links.lww.com/NXI/A250) showed associations of sNfL...
and clinical aspects. The longitudinal analysis revealed a significant effect of a relapse ≤90 days ago on sNfL levels. During follow-up, higher sNfL levels were associated with higher EDSS scores, whereas treatment was associated with lower sNfL levels. There was also an association between sNfL and age with higher levels in younger children.

### Table 1 Baseline data and patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>IFN group</th>
<th>Switching DMT group</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>55</td>
<td>27</td>
<td>28</td>
</tr>
<tr>
<td>Age</td>
<td>14.9 (12.7, 15.6)</td>
<td>14.9 (12.7, 15.7)</td>
<td>14.3 (12.8, 15.6)</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>34/21 (62/38)</td>
<td>16/11 (59/41)</td>
<td>18/10 (64/36)</td>
</tr>
<tr>
<td>EDSS score</td>
<td>0.0 (0.0, 1.0)</td>
<td>0.0 (0.0, 1.0)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>Disease duration (mo)</td>
<td>0.0 (0.0, 4.5)</td>
<td>0.0 (0.0, 1.0)</td>
<td>2.0 (0.0, 10.0)</td>
</tr>
<tr>
<td>Relapses ≤90 d ago</td>
<td>31 (56.4)</td>
<td>16 (59.3)</td>
<td>15 (53.6)</td>
</tr>
<tr>
<td>Follow-up time (mo)</td>
<td>31.8 (24.2, 48.9)</td>
<td>30.8 (26.4, 42.9)</td>
<td>38.0 (23.3, 55.0)</td>
</tr>
<tr>
<td>T2w lesion number available</td>
<td>35 (63.6)</td>
<td>20 (74.1)</td>
<td>16 (57.1)</td>
</tr>
<tr>
<td>No. of T2w lesions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1</td>
<td>2 (5.6)</td>
<td>2 (10.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>2–9</td>
<td>11 (33.3)</td>
<td>9 (45.0)</td>
<td>3 (18.8)</td>
</tr>
<tr>
<td>&gt;9</td>
<td>22 (61.1)</td>
<td>9 (45.0)</td>
<td>13 (81.2)</td>
</tr>
<tr>
<td>CEL lesion number available</td>
<td>39 (70.9)</td>
<td>22 (81.5)</td>
<td>17 (60.7)</td>
</tr>
<tr>
<td>No. of CELs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>16 (41.0)</td>
<td>10 (45.5)</td>
<td>6 (35.3)</td>
</tr>
<tr>
<td>1</td>
<td>5 (12.8)</td>
<td>4 (18.2)</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>2</td>
<td>6 (15.4)</td>
<td>3 (13.6)</td>
<td>3 (17.6)</td>
</tr>
<tr>
<td>≥3</td>
<td>12 (30.8)</td>
<td>5 (22.7)</td>
<td>7 (41.2)</td>
</tr>
<tr>
<td>Treatment at baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Untreated</td>
<td>43 (78.2)</td>
<td>25 (92.6)</td>
<td>18 (64.3)</td>
</tr>
<tr>
<td>IFN/GA</td>
<td>10 (18.2)</td>
<td>2 (7.4)</td>
<td>8 (28.6)</td>
</tr>
<tr>
<td>Nat</td>
<td>2 (3.6)</td>
<td>—</td>
<td>2 (7.1)</td>
</tr>
<tr>
<td>Treatment sequence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>during follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN</td>
<td>27 (49.1)</td>
<td>27 (100)</td>
<td>—</td>
</tr>
<tr>
<td>IFN/GA—FTY</td>
<td>18 (32.7)</td>
<td>—</td>
<td>18 (64.3)</td>
</tr>
<tr>
<td>IFN/GA—DF—FTY</td>
<td>1 (1.8)</td>
<td>—</td>
<td>1 (3.6)</td>
</tr>
<tr>
<td>IFN/GA—Nat—FTY</td>
<td>5 (9.1)</td>
<td>—</td>
<td>5 (17.9)</td>
</tr>
<tr>
<td>FTY—Nat</td>
<td>1 (1.8)</td>
<td>—</td>
<td>1 (3.6)</td>
</tr>
<tr>
<td>Nat—FTY</td>
<td>3 (5.5)</td>
<td>—</td>
<td>3 (10.7)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CEL = contrast-enhancing lesion; DF = dimethyl fumarate; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; FTY = fingolimod; GA = glatiramer acetate; IFN = interferon; Nat = natalizumab.

Data are presented as median with interquartile range and as numbers with percent. The switching DMT group includes patients with different treatment sequences as presented in the table.

* Marks fingolimod group (n = 18 patients who switched from IFN/GA to fingolimod during follow-up).

**sNfL under disease-modifying treatment with IFN-β**

In the IFN group (figure 4A), patients had elevated sNfL levels at baseline with median sNfL >99th percentile of controls and sNfL >90th percentile in 20 of 24 (83%) patients. sNfL levels decreased significantly already after 6 ±
2 months of treatment. During follow-up under IFN treatment, sNfL levels stayed decreased but did not reach values of controls, i.e., patients’ median sNfL levels remained above the 80th percentile of controls up to 30 ± 2 months of follow-up. Figure 5, A and B are examples of 2 individual disease courses.

**SNFL during treatment switch to fingolimod**

In the fingolimod group (figure 4B), patients had elevated sNfL levels with a median sNfL >99th percentile of controls and sNfL >90th percentile in 94% of patients before switch from IFN/GA to fingolimod. After treatment switch, median sNfL levels decreased significantly after 6 ± 2 months of fingolimod.

**Figure 1** sNfL in a control cohort

![Image](https://example.com/image1.png)

Data for sNfL vs age in neurologically healthy controls (n = 301). Vertical lines denote the age range covered by the MS cohort. Specific percentiles were calculated from these samples within the MS age range (n = 212) and are shown as horizontal lines with sNfL percentile values in pg/mL. A nonparametric smoothing line (loess) is shown in blue. There is an age dependency of sNfL with lower levels in younger children (CI [0.963, 0.985], p < 0.001) that is not shown for the controls covering the age range of the MS cohort (CI [0.998, 1.026], p = 0.092). Percentiles are not stratified by sex because there was no significant effect on sNfL. sNfL = serum neurofilament light chain.

**Figure 2** Untreated pediatric patients with MS show elevated sNfL levels compared with controls

![Image](https://example.com/image2.png)

Untreated patients at baseline (n = 43) reveal elevated sNfL levels compared with controls of the same age range (n = 212; CI [4.732, 6.911], p < 0.001) with a median sNfL of 19.0 pg/mL [11.7, 43.8] vs 4.6 pg/mL [3.5, 6.0]. Data are shown as boxplots with median and interquartile range. sNfL = serum neurofilament light chain.
treatment but remained >80th percentile of controls during 12 months of follow-up. Figure 5, C and D shows 2 individual disease courses.

There were no differences in the sNfL levels between patients with (9 patients, sNfL 16.5 pg/mL [10.4, 21.7]) or without a relapse within 90 days before switch from IFN/GA to...
Figure 4 sNfL during DMT

(A) sNfL levels decrease under DMT with IFN. In the IFN group, patients with IFN treatment show elevated sNfL levels at baseline (median 14.7 pg/mL [9.5, 43.0]). sNfL levels decreased significantly under DMT with IFN already after 6 ± 2 months of treatment (7.9 pg/mL; CI [0.339, 0.603], \( p < 0.001 \)), but median sNfL levels stay above the 80th percentile of controls during follow-up. (B) sNfL levels decrease after switch from IFN/GA to fingolimod. Patients switching from IFN or GA to fingolimod during follow-up (fingolimod group) mostly had sNfL levels above the 99th percentile of controls before treatment switch. After treatment switch, sNfL levels decreased significantly from 16.5 pg/mL (12.8; 26.7) to 10 pg/mL (9.5; 43.0) after 6 ± 2 months of fingolimod treatment (CI [0.481, 0.701], \( p < 0.001 \)) but stayed above the 80th percentile of controls during follow-up. All data are shown as boxplots with median and interquartile range. Percentiles of controls are marked by lines. DMT = disease-modifying therapy; GA = glatiramer acetate; IFN = interferon; sNfL = serum neuronfilament light chain.
Figure 5 Individual disease courses demonstrate potential prognostic value of sNfL as a biomarker

(A) Patient 61, IFN group. Diagnosed at age 15.3 years, treatment with IFN, follow-up for 30 months. No relapses and only 1 CEL were detected after 12 months. sNfL levels never dropped below the 90th percentile and only once (after 12 months) below the 99th percentile. (B) Patient 78, IFN group. Diagnosed at age 7.5 years, IFN treatment, follow-up for 105 months. The patient had 1 relapse 6 months after treatment start and after that no clinical or MRI disease activity anymore. sNfL levels were increased before treatment start and dropped under DMT; levels at follow-up were always below the 80th percentile of controls. (C) Patient 14, fingolimod group. Diagnosed at age 7.2 years, initial IFN treatment for 6 years with a relapse rate of 0.5 per year and in the first 3 years each 1 CEL at 3 time points. sNfL levels were always above the 90th percentile apart from 1 measurement after 35 months. After treatment switch to fingolimod after 66 months due to ongoing clinical and MRI disease activity, there was no relapse or cranial CEL during 12 months of follow-up. sNfL levels dropped below the 90th percentile after 6 months and below the 80th percentile after 12 months of fingolimod treatment. (D) Patient 33, fingolimod group. Diagnosed at age 14.3 years, initial IFN treatment. At age 15.6 years, treatment switch to fingolimod due to ongoing clinical and MRI disease activity. Follow-up under treatment with fingolimod was 22 months without any relapse or CEL detection. sNfL levels were elevated at the time point of switch and decreased under fingolimod treatment; levels below the 90th percentile were reached 22 months later. sNfL levels are shown as (x) connected with a broken line, EDSS levels are shown as blue numbers, numbers of CELs are marked with red asterix (*), green lines show the 50th and 90th percentiles of controls, and red arrows (↑) mark relapses. CEL = contrast-enhancing lesion; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; sNfL = serum neurofilament light chain.
fingolimod (8 patients, 17.4 pg/mL [13.1, 29.4]; CI [0.365, 2.080], p = 0.738).

**sNfL in patients with MS without clinical or MRI disease activity**

There were 191 samples from patients with MS with no CEL in cranial MRI at the time of sampling and no recent relapse within 90 days before sampling. These patients without clinical or MRI disease activity had a median sNfL level of 7.2 pg/mL [5.5, 11.9] with a range from 3.0 to 65.5 pg/mL. Hence, there are patients without clinical or MRI disease activity but elevated sNfL levels (figure 5A).

**Discussion**

In adult-onset MS and other neuroinflammatory and neurodegenerative diseases, sNfL appears to be a promising biomarker for disease activity and disability prognosis. In this study, we showed that sNfL may be a useful biomarker for disease activity and treatment monitoring in pediatric MS.

In healthy children, we revealed lower sNfL levels than those in adult cohorts described in the literature. It has been demonstrated that NfL levels in healthy adults are age dependent with an annual increase in sNfL of 2.2%. In our study, we also showed an age dependency but with higher sNfL levels in younger healthy children (figure 1). This could reflect cell migration and cell differentiation including neuronal remodeling processes in the developing brain as recently shown for neurofilament heavy chain in infants. Furthermore, a correlation with the development of the blood-brain barrier and CSF flow rate is conceivable. The albumin quotient, a well-known CSF diagnostic marker, shows a similar dynamic with high levels after birth, a decrease in childhood, and increasing levels in older individuals. In the age range covering the MS cohort, there were no age-dependent differences in the controls. Further analysis involving young adults will identify the age at which the age-associated increase in NfL levels may begin.

Because of high comparability offered by studies with the NF-Light Advantage Kit (Quanterix), our percentiles for sNfL in pediatric controls (figure 1) are usable for future sNfL investigations not only in pediatric MS but also for other childhood-onset neuroinflammatory and neurodegenerative diseases.

We showed associations of sNfL with MRI and clinical disease activity (figures 2 and 3 and figure e-1, links.lww.com/NXI/A250). However, because of low EDSS values in pediatric MS in general, the EDSS data need careful interpretation and the score may only roughly reflect the clinical status. Alternative scores or methods to record clinical status in pediatric MS may improve future studies.

Whereas we did not see an age dependency in the controls covering the MS age range, in the MS cohort, we observed an association between sNfL and age with higher sNfL levels in younger patients (figure e-1, links.lww.com/NXI/A250). This finding is consistent with histologic observations for pediatric MS lesions, where the amount of acutely damaged axons inversely correlated with the patients’ age. In addition, earlier studies on CSF biomarkers showed age correlations of NfL with highest levels in younger children with neurologic diseases. On the other hand, phenomena such as regression to the mean or function of treatment effect could be involved here. For investigating whether there is higher disease activity in children with very early MS diagnosis (age <10 years) in general, a larger cohort has to be analyzed.

In clinical settings, treatment decisions and the question whether the effect of a DMT is sufficient are one of the great challenges. In pediatric MS, IFN and GA continue to be the standard first-line immunomodulatory treatments. According to the high level of inflammation and due to the large proportion of >40% of children with highly active MS, these first-line therapies are often not sufficient. However, treatment decisions, especially switching to higher potent second-line drugs, are complicated by the fact that most of the new and high potent immunomodulatory drugs are not approved for children and long-term efficacy and safety data are missing. Nevertheless, the introduction of higher-efficacy drugs such as fingolimod or natalizumab has improved the clinical course of pediatric patients with highly active MS. Decision criteria, preferably based on signs of current disease activity and expected disease course, will help to weigh the benefits of more potent therapy and the risks of potential side effects for individual patients and improve individualized treatment. Our study shows that sNfL levels decrease significantly under DMT (figure 4A). Because an untreated pediatric MS control group is missing and cannot be investigated for ethical reasons, we cannot exclude the possibility that sNfL levels will decrease over time even in untreated patients. In patients with ongoing clinical or MRI disease activity under DMT with IFN/GA, reflected by elevated sNfL values, switching to a more potent drug (from IFN/GA to fingolimod) led to a significant decline in sNfL (figure 4B). The same was already shown for adult patients with MS. In addition, our data show a tendency toward a later escalation of therapy with higher NfL values at the time of diagnosis.

For an additional benefit over MRI and clinical evaluation alone, a serum biomarker should detect subclinical disease activity. We found 3 aspects supporting that sNfL is able to do so: (1) Patients under DMT did not reach sNfL levels observed in controls, even when effective clinical and MRI disease control was observed. In the IFN group with satisfying clinical and MRI disease control, median sNfL levels stayed above the 80th percentile during 30 months of follow-up (figure 4A). We showed the same for patients in the fingolimod group up to 12 months after switch from IFN/GA to fingolimod (figure 4B), with the limitation that long-term data are missing for this group. (2) In patients switching from IFN/GA to fingolimod, sNfL levels at the time point of switch were elevated but not significantly influenced by a relapse less than 90 days ago. (3) In...
patients with no acute clinical or MRI disease activity, the median sNfL level was above the 80th percentile of controls with a range from 3.0 to 65.5 pg/mL. These results underline that there is subclinical disease activity with ongoing neuroaxonal damage reflected by sNfL measurements.

Nevertheless, it is possible to normalize sNfL values under DMT. Figure 5 describes individual disease courses and gives an idea how sNfL could be used in clinical practice. It is possible to detect treatment responder (figure 5, B and D) and nonresponder (figure 5C) and especially patients with subclinical disease activity (figure 5A).

One limitation of our study is the retrospective design and therefore a missing standardized treatment and follow-up. In addition, as a national center for pediatric MS, we probably see a disproportionally high number of patients with more severe disease courses potentially leading to a bias exaggerating differences between controls and MS population. Moreover, cohorts for highly active MS treated with natalizumab, rituximab, alemtuzumab, and others are not or only insufficiently included and should be analyzed in further studies. To investigate the potential long-term prediction of sNfL for disease course, brain atrophy, cognition, and EDSS worsening, as shown for adult patients,19,21,24,25,38 long-term studies covering the transition from pediatric to adult medical care are needed.

Recently, van der Vuurst de Vries et al.27 showed that CSF NfL is a promising predictive marker for disease course in children with CIS and later MS diagnosis. In addition to these findings, the results of this study highly suggest that sNfL is also a useful biomarker for monitoring disease activity and treatment response in pediatric MS. Access via blood samples, made possible by the Simoa technology,19,40 with high correlations to CSF measurements19,28,41,42 is an important step toward everyday clinical practice implementation, especially in the pediatric setting. sNfL has the potential to guide treatment decisions to an individualized treatment regime, especially in patients with highly active disease course and the necessity of change in therapy due to ongoing or recurring disease activity. A treatment goal of reaching sNfL levels, e.g., below the 90th percentile could be a possible strategy for future individualized treatment decisions, yet the clinical relevance of a certain threshold should first be evaluated in long-term studies. In addition, in the case of particularly high sNfL values at disease onset, this biomarker might be the basis to directly start a highly potent immunomodulatory therapy.

Acknowledgment
The authors thank Ellen Krämer for excellent technical assistance.

Study funding
This study was financially supported by Novartis Pharma AG, Basel, Switzerland. The authors acknowledge support by the Open Access Publication Funds of the Göttingen University.

Disclosure
H. Kropshofer and D. Tomic are full-time employees and stock holder of Novartis Pharma AG, which manufactures one of the drugs investigated in the study. D. Leppert has been an employee of Novartis until January 2019. M.-C. Reinert reports grants from Novartis Pharma AG during the conduct of the study. J. Gärtner reports grants from Novartis Pharma AG during the conduct of the study and personal fees from Bayer Vital, Biogen, and Novartis, outside the submitted work. W. Brück reports grants and personal fees from Novartis during the conduct of the study and personal fees from Bayer Vital, Merck Serono, and Rewind, grants and personal fees from Biogen, Teva Pharma, Sanofi-Genzyme, and Novartis, and grants from MedDay, outside the submitted work. C. Barro reports conference travel grant from Novartis, outside the submitted work. J. Kuhle reports grants from Biogen, Novartis, Roche, Teva, the Swiss MS Society, Genzyme, the University of Basel Swiss National Research Foundation, Bayer Vital, Merck, and Celgene, outside the submitted work. Peter Huppke reports personal fees from Novartis, Bayer Vital, and Merck Serono, outside the submitted work. P. Benkert, J. Wuerfel, Z. Michalak, E. Ruberte, and W. Stark report no disclosures. Go to Neurology.org/NN for full disclosures.

Publication history
Received by Neurology: Neuroimmunology & Neuroinflammation August 20, 2019. Accepted in final form April 9, 2020.

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie-Christine Reinert, MD</td>
<td>University Medical Centre, Göttingen, Germany</td>
<td>Designed the study; major role in the acquisition of data; interpreted the data; and drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Pascal Benkert, PhD</td>
<td>University of Basel, Switzerland</td>
<td>Analyzed the data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Jens Wuerfel, MD</td>
<td>Medical Image Analysis Centre Basel (MIAC AG), Basel, Switzerland</td>
<td>Analyzed and interpreted the data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Zuzanna Michalak, PhD</td>
<td>University of Basel, Switzerland</td>
<td>Analyzed the data</td>
</tr>
<tr>
<td>Esther Ruberte, PhD</td>
<td>Medical Image Analysis Centre Basel (MIAC AG), Basel, Switzerland</td>
<td>Analyzed the data</td>
</tr>
<tr>
<td>Christian Barro, MD</td>
<td>University of Basel, Switzerland</td>
<td>Analyzed the data</td>
</tr>
<tr>
<td>Peter Huppke, MD</td>
<td>University Medical Centre, Göttingen, Germany</td>
<td>Major role in the acquisition of data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Wiebke Stark, MD</td>
<td>University Medical Centre, Göttingen, Germany</td>
<td>Major role in the acquisition of data</td>
</tr>
</tbody>
</table>
Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harald Kropshofer, PhD</td>
<td>Novartis Pharma AG, Basel, Switzerland</td>
<td>Conceptualization of the study; interpreted the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Davorka Tomic, PhD</td>
<td>Novartis Pharma AG, Basel, Switzerland</td>
<td>Interpreted the data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>David Leppert, MD</td>
<td>University of Basel, Switzerland</td>
<td>Conceptualization of the study; interpreted the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Jens Kuhle, MD, PhD</td>
<td>University of Basel, Switzerland</td>
<td>Conceptualization of the study; analyzed and interpreted the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Wolfgang Bruck, MD</td>
<td>University Medical Centre, Göttingen, Germany</td>
<td>Conceptualization of the study; interpreted the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Jutta Gartner, MD</td>
<td>University Medical Centre, Göttingen, Germany</td>
<td>Design and conceptualization of the study; interpreted the data; and revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

References

Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
Marie-Christine Reinert, Pascal Benkert, Jens Wuerfel, et al.
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000749

This information is current as of May 13, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/7/4/e749.full.html

References
This article cites 41 articles, 2 of which you can access for free at:
http://nn.neurology.org/content/7/4/e749.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Pediatric
http://nn.neurology.org/cgi/collection/all_pediatric
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.